US EditionAvidity announces positive topline data from DMD clinical trial skipping exon 44
Summary by CureDuchenne
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Avidity announces positive topline data from DMD clinical trial skipping exon 44
CureDuchenne provided early funding to Avidity Biosciences, and are pleased to share they have released positive topline data from the EXPLORE44 trial in individuals amenable to skipping exon 44. Data was consistent across two cohorts, dosed either with 5 mg/kg every 6 weeks or 10 mg/kg every 8 weeks. Delpacibart zotadirsen (abbreviated as del-zota) demonstrated statistically significant increases of approximately 25% of normal dystrophin prod…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
